EUR/USD
1.16913
0.027%
Gold
4466.65
-0.625%
Oil
56.616
-0.359%
USD/JPY
156.466
-0.128%
GBP/USD
1.35016
0.001%
GBP/JPY
211.260
-0.062%
Real-time News
On January 7th, Zhenxin Technology announced that, according to a notice issued by the Military Procurement Network on January 6th, 2026, the Joint Staff Department of the Western Theater Command, in accordance with relevant regulations on military supplier management, has decided to ban Chengdu Guoxing Communication Co., Ltd., a subsidiary of Chengdu Zhenxin Technology Co., Ltd., from participating in material and engineering service procurement activities within the Western Theater Command for three years, effective January 6th, 2026. An investigation confirmed that Guoxing Communication engaged in bid rigging and other irregularities in the procurement activity for project number 2020-ZCWDDK-W1002. Currently, the company and its subsidiarys overall production and operation activities are normal. During the ban period, Guoxing Communication cannot participate in material and engineering service procurement activities within the Western Theater Command (headquarters and directly affiliated units). It is expected that this decision will not have a significant impact on the company and its subsidiarys production and operation at present.Xiaomi Group (01810.HK) repurchased 3.9 million Class B shares for HK$148.8 million on January 7.On January 7th, CIMC Group (02039.HK) announced that it holds a 45.92% stake in Shenzhen CIMC Industrial City Development Group Co., Ltd. through its wholly-owned subsidiary, CIMC Shenfa Construction Industry Co., Ltd. CIMC Industrial City recently sold its entire Qianhai CIMC International Business Center East Tower project for approximately RMB 2.534 billion. Preliminary calculations indicate that this transaction is expected to indirectly reduce CIMC Groups net profit attributable to shareholders in 2025 by approximately RMB 1.08 billion.Tencent Holdings (00700.HK): On January 7, it repurchased 1.023 million shares, costing approximately HK$640 million.On January 7th, Hengrui Medicine announced that its subsidiary, Suzhou Shengdiya Biopharmaceutical Co., Ltd., received notification from the National Medical Products Administration (NMPA) approving the marketing of its independently developed Class 1 innovative drug, Relavop α Injection. This drug, in combination with fluorouracil and platinum-based drugs, is indicated for first-line treatment of PD-L1-positive locally advanced unresectable, recurrent, or metastatic adenocarcinoma of the stomach and gastroesophageal junction, based on well-validated diagnostic criteria. No similar products have been approved for marketing domestically or internationally. To date, the cumulative R&D investment in the Relavop α Injection project has reached approximately RMB 711 million.
